Hydrosoluble fiber (Plantago ovata husk) and levodopa I: Experimental study of the pharmacokinetic interaction

European Neuropsychopharmacology

Volumn 15, Issue 5, 2005, Pages 497-503

  Garcia, Juan J ^a   Fernandez, Nelida ^a   Carriedo, Demetrio ^a   Diez, M Jose ^a   Sahagun, Ana ^a   Gonzalez, Aranzazu ^a   Calle, Angela ^a   Sierra, Matilde ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Fiber; Interaction; Levodopa; Pharmacokinetics; Plantago ovata husk; Rabbits

Indexed keywords

HERBACEOUS AGENT; LEVODOPA; PLANTABEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG POTENTIATION; MEAN RESIDENCE TIME; NONHUMAN; PARKINSON DISEASE; PLANT FIBER; PLANTAGO OVATA; PRIORITY JOURNAL; RABBIT; SEED HUSK;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIETARY FIBER; HUMANS; LEVODOPA; MODELS, ANIMAL; PHYTOTHERAPY; PLANTAGO; RABBITS;

EID: 24044497213     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.01.005     Document Type: Article

References (39)

1. I. Andersson, A.K. Granerus, R. Jagenburg, and A. Svanborg Intestinal decarboxylation of orally administered l-dopa: influence of pharmacological preparations, dose magnitude, dose sequence and food intake Acta Med. Scand. 198 1975 415 420
2. R. Astarloa, M.A. Mena, V. Sanchez, L. de la Vega, and J.G. de Yebenes Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease Clin. Neuropharmacol. 15 1992 375 380
3. M. Bianchi, and L. Capurso Effects of guar gum, ispaghula and microcrystalline cellulose on abdominal symptoms, gastric emptying, orocaecal transit time and gas production in healthy volunteers Dig. Liver Dis. 34 2002 S129 S133
4. E. Bredberg, J. Tedroff, S.M. Aquilonius, and L. Paalzow Pharmacokinetics and effects of levodopa in advanced Parkinson's disease Eur. J. Clin. Pharmacol. 39 1990 385 389
5. K.G. Byrne, R.F. Pfeiffer, and E.M. Quigley Gastrointestinal dysfunction in Parkinson's disease: a report of clinical experience at a single center J. Clin. Gastroenterol. 19 1994 11 16
6. T.N. Chase, T.M. Engber, and N.M. Mouradian Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease Neurology 44 1994 S15 S18
7. A.C. Chiu, and S.I. Sherman Effects of pharmacological fiber supplements on levothyroxine absorption Thyroid 8 1998 667 671
8. M. Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, and A. Baruzzi Pharmacodynamic modelling of oral levodopa: clinical application in Parkinson's disease Neurology 43 1993 367 371
9. M. Contin, R. Riva, F. Albani, and A. Baruzzi Pharmacokinetic optimisation in the treatment of Parkinson's disease Clin. Pharmacokinet. 30 1996 463 481
10. D. Deleu, S. Sarre, G. Ebinger, and Y. Michotte In vivo pharmacokinetics of levodopa and 3-O-methyldopa in muscle: a microdialysis study Naunyn Schmiedeberg's Arch. Pharmacol. 344 1991 514 519
11. L.L. Edwards, E.M.M. Quigley, and R.F. Pfeiffer Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology Neurology 42 1992 726 732
12. M.A. Etman Effect of a bulk forming laxative on the bioavailability of carbamazepine in man Drug Dev. Ind. Pharm. 21 1995 1901 1906
13. A.B. Ettinger, S. Shinnar, M.J. Sinnett, and S.L. Moshe Carbamazepine-induced constipation J. Epilepsy 5 1992 191 193
14. N. Fernández, M.J. Diez, M.T. Terán, J.J. García, A.P. Calle, and M. Sierra Influence of two commercial fibers in the pharmacokinetics of ethinilestradiol in rabbits J. Pharmacol. Exp. Ther. 286 1998 870 874
15. G.S. Frost, A.E. Brynes, W.S. Dhillo, S.R. Bloom, and M.I. McBurney The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal Eur. J. Clin. Nutr. 57 2003 293 298
16. S.T. Gancher, J.G. Nutt, and W.R. Woodward Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating Parkinsonian patients Neurology 37 1987 940 944
17. J.J. García, N. Fernández, M.J. Diez, A. Sahagún, A. González, M.L. Alonso, C. Prieto, A.P. Calle, and M. Sierra Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol Contraception 62 2000 253 257
18. W.R. Garnett Gastrointestinal dysmotility and central nervous system disorders: use of cisapride in patients with Parkinson's disease Consult. Pharm. 11 1996 10 16
19. M. Gibaldi, and D. Perrier Multicompartment Models 2nd ed. Pharmacokinetics 1982 Marcel Dekker New York
20. S. Grange, N.H. Holford, and T.W. Guentert A pharmacokinetic model to predict the PK interaction of l-dopa and benserazide in rats Pharm. Res. 18 2001 1174 1184
21. J.P. Hammerstad, W.R. Woodward, P. Gliessman, B. Boucher, and J.G. Nutt l-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys Ann. Neurol. 27 1990 495 499
22. W.E. Hansen Effect of dietary fiber on proteolytic pancreatic enzymes in vitro Int. J. Pancreatol. 1 1986 341 351
23. G. Isaksson, I. Lundquist, and I. Ihse Effect of dietary fiber on pancreatic enzyme activity in vitro Gastroenterology 82 1982 918 924
24. E. Leng-Peschlow Interference of dietary fibres with gastrointestinal enzymes in vitro Digestion 44 1989 200 210
25. E. Leng-Peschlow Plantago ovata seeds as dietary fibre supplement, physiological and metabolic effects in rats Br. J. Nutr. 66 1991 331 349
26. H. Lennernäs, D. Nilsson, S.M. Aquilonius, O. Ahrenstedt, L. Knutson, and L.K. Paalzow The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man Br. J. Clin. Pharmacol. 35 1993 243 250
27. Y. Liel, I. Harman-Boehm, and S. Shany Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients J. Clin. Endocrinol. Metab. 81 1996 857 859
28. M.M. Mouradian, I.J. Heuser, F. Baronti, and T.N. Chase Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease Ann. Neurol. 27 1990 18 23
29. M. Murata, and I. Kanazawa Effects of chronic levodopa therapy on dopa pharmacokinetics Eur. Neurol. 38 1997 50 55
30. D. Nilsson, U. Fagerholm, and H. Lennernas The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum Pharm. Res. 11 1994 1540 1547
31. J.G. Nutt On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics Ann. Neurol. 22 1987 535 540
32. J.G. Nutt, and J.H. Fellman Pharmacokinetics of levodopa Clin. Neuropharmacol. 7 1984 35 49
33. B.B. Perlman Interaction between lithium salts and ispaghula husk Lancet 17 1990 335
34. J.M. Rabey, M. Schwartz, E. Graff, A. Harsat, and Y. Vered The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease Clin. Neuropharmacol. 14 1991 514 522
35. D. Rigaud, F. Paycha, A. Meulemans, M. Merrouche, and M. Mignon Effect of psyllium on gastric emptying, hunger feeling and food intake in normal volunteers: a double blind study Eur. J. Clin. Nutr. 52 1998 239 245
36. L. Rivera-Calimlim, C.A. Dujovne, J.P. Morgan, L. Lasagna, and J.R. Bianchine l-dopa treatment failure: explanation and correction Br. Med. J. 10 1970 93 94
37. S. Rose, P. Jenner, and C.D. Marsden Peripheral pharmacokinetic handling and metabolism of l-dopa in the rat: the effect of route of administration and carbidopa pretreatment J. Pharm. Pharmacol. 43 1991 325 330
38. J. Russell, and P. Bass Canine gastric emptying of fiber meals: influence of meal viscosity and antroduodenal motility Am. J. Physiol. 249 1985 G662 G667
39. K. Sasahara, T. Nitanai, T. Habara, T. Morioka, and E. Nakajima Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and Parkinsonian patients J. Pharm. Sci. 69 1980 261 265